Results 211 to 220 of about 32,676 (224)

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Nature Reviews Drug Discovery, 2010
Elisabeth Perzborn, Dagmar Kubitza, Frank Misselwitz   +2 more
exaly  

Rivaroxaban: A New Oral Factor Xa Inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
Elisabeth Perzborn, Dagmar Kubitza, Wolfgang Mueck   +2 more
exaly  

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Circulation, 2016
Jeffrey B Washam, Richard C Becker, Scott D Berkowitz   +2 more
exaly  

Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban

Annals of Pharmacotherapy, 2015
Robert C Gosselin, Stephan Moll, William E Dager   +2 more
exaly  

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British Journal of Clinical Pharmacology, 2013
Wolfgang Mueck, Dagmar Kubitza, Michael Becka   +2 more
exaly  

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation

Stroke, 2017
Ying Bai, Alena Shantsila
exaly  

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical Pharmacokinetics, 2013
Wolfgang Mueck, Dagmar Kubitza, Michael Becka   +2 more
exaly  

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Clinical Pharmacokinetics, 2012
Wolfgang Mueck, Kenneth A Bauer, Ola E Dahl   +2 more
exaly  

Pharmacodynamic and pharmacokinetic basics of rivaroxaban

Fundamental and Clinical Pharmacology, 2012
Reinhold Kreutz
exaly  

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

Journal of Thrombosis and Haemostasis, 2015
I J Mackie, Maria Efthymiou, D A Isenberg   +2 more
exaly